SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001725160-22-000075
Filing Date
2022-04-11
Accepted
2022-04-11 16:37:07
Documents
12
Period of Report
2022-04-08
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20220408.htm   iXBRL 8-K/A 43939
  Complete submission text file 0001725160-22-000075.txt   185055

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20220408.xsd EX-101.SCH 1914
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20220408_lab.xml EX-101.LAB 24993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20220408_pre.xml EX-101.PRE 13190
6 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20220408_htm.xml XML 11279
Mailing Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39263 | Film No.: 22820062
SIC: 2834 Pharmaceutical Preparations